Antiangiogenic and hypolipidemic activity of coenzyme Q_{10} supplementation to breast cancer patients undergoing Tamoxifen therapy

Issue title: The Fifth Conference of the International CoQ10 Association, Kobe 2007 – 50th anniversary of CoQ10 discovery

Article type: Research Article

Authors: Sachdanandam, Panchanatham

Affiliations: Department of Medical Biochemistry, DR. ALM Post-Graduate Institute of Basic Medical Sciences, University of Madras, Taramani Campus, Chennai – 600 113, Tamil Nadu, India. Tel.: +91 44 24547089; Fax: +91 44 24540709; E-mail: [email protected]

Abstract: Tamoxifen, a non-steroidal anti-estrogen is now widely used and has led to an increase in both disease-free and overall survival of women after primary surgery. Tamoxifen therapy is found to cause hypertriglyceridemia by reducing activity of lipolytic enzymes on triglycerides, and thereby increasing the risk of cardiovascular disease. Angiogenesis promotes local tumour progression and invasion and enables tumour cell dissemination and metastasis formation. Our study has found that co-administration of Coenzyme Q_{10} (100 mg) along with tamoxifen (10 mg, twice a day) to breast cancer patients reduced the level of angiogenesis markers and lipid levels.

Keywords: Breast cancer, Tamoxifen, Coenzyme Q[TeX:] _{10}, angiogenesis, hypolipidemia, tumour markers

Journal: BioFactors, vol. 32, no. 1-4, pp. 151-159, 2008